PF-Atlas › Mechanisms › CRISPR Base Editing

CRISPR Base Editing in IPF

Mechanism of action · idiopathic pulmonary fibrosis

Overview

CRISPR Base Editing is a therapeutic target in idiopathic pulmonary fibrosis. PF-Atlas tracks 1 drug and 1 clinical trial acting through this mechanism.

Drugs targeting CRISPR Base Editing

BEAM-302

Clinical trials

BEAM-302 — BEAM-AATD

Medical disclaimer. This is a research summary, not medical advice.